Helius Medical Technologies, Inc. (NASDAQ:HSDT) Short Interest Update

Helius Medical Technologies, Inc. (NASDAQ:HSDTGet Rating) was the target of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 14,300 shares, a decrease of 31.9% from the April 15th total of 21,000 shares. Based on an average daily volume of 16,700 shares, the short-interest ratio is currently 0.9 days.

Institutional investors have recently added to or reduced their stakes in the company. Delta Investment Management LLC bought a new position in shares of Helius Medical Technologies in the third quarter worth $535,000. Altium Capital Management LP bought a new position in shares of Helius Medical Technologies in the fourth quarter worth $254,000. ACT Capital L.L.C. increased its stake in Helius Medical Technologies by 19.3% in the third quarter. ACT Capital L.L.C. now owns 70,616 shares of the company’s stock valued at $1,017,000 after acquiring an additional 11,430 shares during the last quarter. Kepos Capital LP increased its stake in Helius Medical Technologies by 296.4% in the fourth quarter. Kepos Capital LP now owns 100,304 shares of the company’s stock valued at $521,000 after acquiring an additional 75,000 shares during the last quarter. Finally, AIGH Capital Management LLC bought a new position in Helius Medical Technologies in the fourth quarter valued at $1,298,000. 29.74% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:HSDT traded up $0.12 during trading on Friday, hitting $1.60. 58,701 shares of the company were exchanged, compared to its average volume of 29,105. The stock has a 50 day moving average of $2.99 and a 200 day moving average of $5.00. Helius Medical Technologies has a 52-week low of $1.35 and a 52-week high of $17.26.

Helius Medical Technologies (NASDAQ:HSDTGet Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.02). Helius Medical Technologies had a negative return on equity of 232.55% and a negative net margin of 3,043.95%. During the same quarter in the prior year, the firm posted ($1.65) earnings per share. On average, analysts expect that Helius Medical Technologies will post -4.48 earnings per share for the current fiscal year.

Separately, Zacks Investment Research downgraded Helius Medical Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, January 20th.

Helius Medical Technologies Company Profile (Get Rating)

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.

See Also

Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.